There is one clinical trial.
Facing the unusual situation imposed by the coronavirus disease, the aim of this study is to evaluate the risk and effects of less frequent hemodialysis on prevalent patients
Description: Time to all-cause and cardiovascular deathMeasure: Mortality Time: From date of beginning of the study until the date of death assessed up to 52 weeks
Description: Time variation of the biological parameters mentioned in the title. Repeated measurements of laboratory variables will be averaged into patient quarterly means to minimize measurement variability.Measure: Anemia, Nutrition, Adequation of dialysis, total ultrafiltration, ultrafiltration rate, Time: From date of beginning of the study assessed up to 52 weeks
Description: Time to first hospitalization of any causeMeasure: Hospitalization Time: From date of beginning of the study until the date of first hospitalization assessed up to 52 weeks
Description: Time to first endovascular or quirurgical intervention of the vascular access utilized at the start of the studyMeasure: Vascular Access Time: From date of beginning of the study until the date of first intervention assessed up to 52 weeks
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports